A commentary just out in the journal Critical Care made those same points:
Some have argued that the campaign is simply advanced marketing for activated protein C. That Eli Lilly are interested in promoting education in the field of sepsis because they have a product to treat sepsis is unquestionably true. But the multiple checks and balances outlined above prevent any direct influence in the guidelines content. While the consensus process included a number of proponents of activated protein C, it also included some of activated protein C's more vocal critics. If Eli Lilly's primary objective is to cast their drug in a favourable commercial light, they have shown questionable judgment in supporting the SSC, as the current recommendation for activated protein C use in sepsis is a weak one.